Content about Genzyme

February 18, 2011

DEERFIELD, Ill. — Walgreens this month rounded out the pharmacy purchasing team led by Jeff Berkowitz, who joined the company in the fall as SVP pharmaceutical development and market access.


February 16, 2011

French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

CAMBRIDGE, Mass. — French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

January 26, 2011

Watson Pharmaceuticals is seeking regulatory approval for a generic drug for high cholesterol.

MORRISTOWN, N.J. — Watson Pharmaceuticals is seeking regulatory approval for a generic drug for high cholesterol.

Watson, through subsidiary Watson Labs, said it applied for approval of a generic version of Daiichi Sankyo’s and Genzyme’s Welchol (colesevelam hydrochloride). The drug, a powdered oral suspension, is used to reduce “bad” LDL cholesterol in patients with primary hyperlipidemia, either alone or in combination with a statin.

January 20, 2011

Finalizing an acquisition of biotech company Genzyme by French drug maker Sanofi-Aventis “will take some time,” media reports quoted Genzyme’s chief executive as saying.

BOSTON — Finalizing an acquisition of biotech company Genzyme by French drug maker Sanofi-Aventis “will take some time,” media reports quoted Genzyme’s chief executive as saying.

The Boston Globe quoted Genzyme CEO Henri Termeer as saying it would be a long process to understand the company’s full value, in particular because of an investigational multiple sclerosis drug, Campath (alemtuzumab), which could achieve blockbuster sales and thus raise the company’s value and acquisition price if it wins approval.

January 10, 2011

It appears that French drug maker Sanofi-Aventis’ efforts to acquire U.S. biotech company Genzyme are getting somewhere, according to company and media reports.

CAMBRIDGE, Mass. — It appears that French drug maker Sanofi-Aventis’ efforts to acquire U.S. biotech company Genzyme are getting somewhere, according to company and media reports.

December 13, 2010

Biotech company Genzyme still is saying “no thanks” to French drug maker Sanofi-Aventis’ tender offer of $18.5 billion, or $69 per share, to acquire it, saying the offer “substantially undervalues” the company.

CAMBRIDGE, Mass. — Biotech company Genzyme still is saying “no thanks” to French drug maker Sanofi-Aventis’ tender offer of $18.5 billion, or $69 per share, to acquire it, saying the offer “substantially undervalues” the company.

The offer has been extended until Jan. 11, Genzyme said.

Sanofi has sought to buy Genzyme since August. Genzyme, based in Cambridge, Mass., specializes in treatments for rare genetic disorders, such as Fabry disease and Gaucher disease.

November 22, 2010

Impax confirmed a patent challenge for its version of a branded cholesterol drug that recently was submitted to the FDA for approval ...

HAYWARD, Calif. A generic drug maker confirmed a patent challenge for its version of a branded cholesterol drug that recently was submitted to the Food and Drug Administration for approval.

Impax said Daiichi Sankyo and Genzyme are seeking to block Impax's generic version of Welchol (colesevelam HCl) for oral suspension, in 3.75 g/packet and 1.875 g/packet strengths. The two drug makers filed suit for patent infringement against Impax in the U.S. District Court for the District of Delaware after being notified that the FDA accepted Impax's ANDA for the drug.

November 17, 2010

Biotech company Genzyme Corp. is selling its diagnostics business to Sekisui Chemical Co. for $265...

CAMBRIDGE, Mass. — Biotech company Genzyme is selling its diagnostics business to Sekisui Chemical for $265 million, Genzyme said Thursday.

 

Under the deal, Sekisui will purchase the diagnostics business’ assets, including product lines and technologies, and offer employment to its 575 employees while maintaining operations in all of its current locations.

 

 

October 7, 2010

The board of directors of Genzyme again has rejected a buyout offer by French drug...

CAMBRIDGE, Mass. The board of directors of Genzyme again has rejected a buyout offer by French drug maker Sanofi-Aventis, Genzyme said Thursday.

The biotech company’s board unanimously turned down the hostile offer Sanofi made Monday to acquire Genzyme for $18.5 billion, or $69 per share, saying it was “opportunistic” and undervalued the company.

 

October 7, 2010

The drug industry is undergoing a major paradigm shift. Companies that traditionally have relied on...

WHAT IT MEANS AND WHY IT'S IMPORTANT The drug industry is undergoing a major paradigm shift. Companies that traditionally have relied on blockbuster drugs are finding that model running dry as their biggest money-makers face competition from generics that eventually will lead to a heavily commoditized market for the disease states that have been the foundation for the model, such as high cholesterol, asthma, mental illness and gastroesophageal reflux disease.

October 3, 2010

French drug maker Sanofi-Aventis has launched a hostile takeover bid to take over Cambridge, Mass.-based...

NEW YORK French drug maker Sanofi-Aventis has launched a hostile takeover bid to take over Cambridge, Mass.-based biotech company Genzyme, according to published reports.

 

The Associated Press reported Monday that Sanofi would try to acquire the company for $18.5 billion, or $69 per share. Genzyme previously had rejected Sanofi’s friendly offer for the same amount.

 

 

September 12, 2010

Laboratory Corp. of America Holdings will purchase a clinical testing business from Genzyme, Genzyme said...

CAMBRIDGE, Mass. Laboratory Corp. of America Holdings will purchase a clinical testing business from Genzyme, Genzyme said Monday.

 

The biotech company said LabCorp would buy Genzyme Genetics, its reproductive and cancer testing unit, for $925 million in cash.

 

 

August 30, 2010

After Sanofi-Aventis sent Genzyme a second proposal letter to acquire the drug maker on Monday,...

CAMBRIDGE, Mass. After Sanofi-Aventis sent Genzyme a second proposal letter to acquire the drug maker on Monday, Genzyme said "the identical offer ... fails to establish a basis for engagement by the Genzyme board."

Sanofi-Aventis offered to acquire Genzyme for $69 per share in cash on two occasions. Prior to Monday's duplicate offer, the first offer was sent to Genzyme on July 29. The drug maker rejected the offer two weeks later.

August 29, 2010

Sanofi-Aventis is looking to acquire Genzyme with a nonbinding proposal valued at approximately $18.5 billion....

August 25, 2010

Biotech drug maker Genzyme’s takeover by French drug maker Sanofi-Aventis may have run into trouble,...

NEW YORK Biotech drug maker Genzyme’s takeover by French drug maker Sanofi-Aventis may have run into trouble, according to published reports.

Bloomberg reported Wednesday that Sanofi was unwilling to raise its offer of $70 per share for Genzyme, a Cambridge, Mass.-based company that has carved a niche for itself by manufacturing treatments for such rare genetic disorders as Fabry disease and Pompe disease but lately has been dogged by manufacturing problems.

August 19, 2010

BioMarin Pharmaceutical has acquired privately owned biotechnology company ZyStor Therapeutics for $22 million, BioMarin said....

August 5, 2010

Biotech company Genzyme and Isis Pharmaceuticals have finished late-stage clinical trials of a cholesterol-lowering drug,...

August 2, 2010

French drug maker Sanofi-Aventis has made an offer for Genzyme, according to published reports....

July 12, 2010

Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals hopes to be the first to market a version of a kidney disease treatment made by Genzyme, Watson said Monday.

Watson said it filed a regulatory approval application with the Food and Drug Administration for sevelamer carbonate for oral suspension. The drug is a generic version of Genzyme’s Renvela, used to control serum phosphorus in patients with chronic kidney disease who are on dialysis.

 

July 7, 2010

Generic drug maker Hospira will fill and package several drugs for Genzyme, according to published...

July 5, 2010

Generic drug maker Impax Labs is challenging the patent on a drug used to treat...

June 14, 2010

The Food and Drug Administration has agreed to speed up the review of a Genzyme...

May 25, 2010

Generic drug maker Watson Pharmaceuticals is challenging the patent on a drug for treating kidney...

May 24, 2010

The Food and Drug Administration has approved a new treatment for a rare genetic disorder...

May 23, 2010

Biotech company Genzyme will pay $175 million to the federal government as part of an...